The long road to diagnosis, from gastroesophageal reflux disease, through Barrett's esophagus, to visceral hypersensitivity: a case report
DOI:
https://doi.org/10.12775/JEHS.2025.77.57199Keywords
visceral hypersensitivity, case report, gastroesophageal reflux disease, irritable bowel syndrome, therapy, small intestine bacterial overgrowthAbstract
Background: Visceral hypersensitivity syndrome is a condition involving excessive perception of mechanical stimuli in the intestines. In patients suffering from this disorder, physiological bowel function causes pain and discomfort.
Case summary: The patient presented is a 26-year-old man with severe gastrointestinal symptoms that were difficult to manage, such as heartburn, pressure in the esophageal region, a sensation of a gullet in the throat, food retention, and frequent belching. The man had been experiencing these symptoms intermittently for four years, during which time he had been treated without success. By way of exclusion, a diagnosis of visceral hypersensitivity was made, and a low dose of amitriptyline was administered. Psychological therapy was also recommended. This treatment brought significant improvement and resulted in the resolution of his complaints.
Conclusions: Visceral hypersensitivity is strongly associated with psychosocial factors, which should be taken into account when treating patients with gastrointestinal disorders. Low doses of amitriptyline may be an effective treatment option.
References
1. Camilleri M. Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut. 2002 Jul;51 Suppl 1(Suppl 1):i34-40. doi: 10.1136/gut.51.suppl_1.i34. PMID: 12077062; PMCID: PMC1867712.
2. Eijkelkamp N, Heijnen CJ, Carbajal AG, Willemen HL, Wang H, Minett MS, Wood JN, Schedlowski M, Dantzer R, Kelley KW, Kavelaars A. G protein-coupled receptor kinase 6 acts as a critical regulator of cytokine-induced hyperalgesia by promoting phosphatidylinositol 3-kinase and inhibiting p38 signaling. Mol Med. 2012 May 9;18(1):556-64. doi: 10.2119/molmed.2011.00398. PMID: 22331028; PMCID: PMC3388142.
3. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil. 2016 Oct 30;22(4):558-574. doi: 10.5056/jnm16001. PMID: 27431236; PMCID: PMC5056566.
4. Farmer AD, Aziz Q. Gut pain & visceral hypersensitivity. Br J Pain. 2013 Feb;7(1):39-47. doi: 10.1177/2049463713479229. PMID: 26516496; PMCID: PMC4590155.
5. Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci. 2001 Nov;46(11):2542-8. doi: 10.1023/a:1012356827026. PMID: 11713967.
6. van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008 Mar;6(3):321-8. doi: 10.1016/j.cgh.2007.12.005. Epub 2008 Feb 7. PMID: 18258487.
7. Kanazawa M, Palsson OS, Thiwan SI, Turner MJ, van Tilburg MA, Gangarosa LM, Chitkara DK, Fukudo S, Drossman DA, Whitehead WE. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008 Oct;103(10):2550-61. doi: 10.1111/j.1572-0241.2008.02066.x. Epub 2008 Aug 5. PMID: 18684175; PMCID: PMC3855425.
8. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol. 2009 Oct;24(10):1601-7. doi: 10.1111/j.1440-1746.2009.05984.x. PMID: 19788601.
9. Ludidi S, Mujagic Z, Jonkers D, Keszthelyi D, Hesselink M, Kruimel J, Conchillo J, Masclee A. Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2014 Aug;26(8):1104-11. doi: 10.1111/nmo.12365. Epub 2014 Jun 11. PMID: 24920528.
10. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24(1):21-37. doi: 10.2165/00019053-200624010-00002. PMID: 16445300.
11. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007 Oct;133(4):1113-23. doi: 10.1053/j.gastro.2007.07.024. Epub 2007 Jul 25. PMID: 17919487.
12. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci. 1995 Apr;40(4):819-27. doi: 10.1007/BF02064986. PMID: 7720476.
13. Ludidi S, Conchillo JM, Keszthelyi D, et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil. 2012;24:729–733. doi: 10.1111/j.1365-2982.2012.01926.x.
14. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;4:125–132. doi: 10.1136/gut.14.2.125.
15. Lee H, Park JH, Park DI, et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil. 2013;19:244–250. doi: 10.5056/jnm.2013.19.2.244
16. Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36:1009–1031. doi: 10.1111/apt.12080.
17. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012;18:258–268. doi: 10.5056/jnm.2012.18.3.258.
18. Thijssen AY, Jonkers DM, Leue C, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol. 2010;44:e236–e241. doi: 10.1097/MCG.0b013e3181eed5d8.
19. Barbara G, Cremon C, De Giorgio R, et al. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep. 2011;13:308–315. doi: 10.1007/s11894-011-0195-7.
20. Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One. 2013;8:e63893. doi: 10.1371/journal.pone.0063893.
21. Wang H, Gong J, Wang W, et al. Are there any different effects of Bifidobacterium, lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in pi-ibs mouse model? PLoS One. 2014;9:e90153.
22. Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290–1298. doi: 10.1038/ajg.2011.86.
23. Leighton MP, Lam C, Mehta S, Spiller RC. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trials. 2013;14:10. doi: 10.1186/1745-6215-14-10.
24. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(suppl 1):S1–S4. doi: 10.1111/j.1572-0241.2005.50613_1.x.
25. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48:272–282. doi: 10.1136/gut.48.2.272.
26. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic anti-depressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15:1548–1553. doi: 10.3748/wjg.15.1548.
27. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci. 2008;4:71–76.
28. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol. 1998;93:160–165. doi: 10.1111/j.1572-0241.1998.00160.x.
29. Thoua NM, Murray CD, Winchester WJ, Roy AJ, Pitcher MC, Kamm MA, Emmanuel AV. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:552–560. doi: 10.1111/j.1365-2036.2008.03918.x.
30. Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, Malekzadeh R. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:678–684. doi: 10.1111/j.1365-2036.2008.03633.x.
31. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:638–648. doi: 10.1111/j.1365-2036.2011.04775.x.
32. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54:601–607. doi: 10.1136/gut.2004.047423.
33. Huang W, Jiang SM, Jia L, You LQ, Huang YX, Gong YM, Wang GQ. Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial. World J Gastroenterol. 2013 Jul 14;19(26):4214-20. doi: 10.3748/wjg.v19.i26.4214. PMID: 23864786; PMCID: PMC3710425.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Małgorzata Wirkijowska, Jolanta Mędyk, Yauheniya Patarocha, Michał Rogulski, Aleksandra Ślusarska, Paulina Błasiak, Patryk Mikołajec, Ruslan Huk, Barbara Bilecka, Jakub Wirkijowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 339
Number of citations: 0
